{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-264693","form_type":"8-K","ticker":"LAB","cik":"0001162194","company_name":"STANDARD BIOTOOLS INC.","filed_at":"2025-11-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.909711+00:00","generated_at":"2026-05-17T00:33:03.954876+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Standard BioTools Q3 revenue $19.6M, net loss $31.7M; restructuring targets $40M savings","bullets":["Revenue from continuing ops $19.6M, down 11% YoY; net loss $31.7M vs $21.9M loss in Q3 2024.","Adjusted EBITDA loss $16.5M vs $13.7M loss; restructuring plan cuts ~20% workforce for $40M annual savings.","Cash $217M at Sept 30; expects ~$550M cash at close of Illumina transaction in H1 2026.","FY2025 revenue guidance reaffirmed: combined $165-175M, continuing ops $78-83M.","Gross margin 48.5% (GAAP) and 53.5% (non-GAAP), down from prior year due to volume and mix."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-264693","json":"https://secwatch.observer/filing/0001193125-25-264693.json","markdown":"https://secwatch.observer/filing/0001193125-25-264693.md","text":"https://secwatch.observer/filing/0001193125-25-264693.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1162194/000119312525264693/0001193125-25-264693-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1162194/000119312525264693/lab-20251104.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T00:33:03.954876+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}